PulmCCM

PulmCCM

Novel oral anticoagulants: reversal agents efficacy compared

PulmCCM's avatar
PulmCCM
May 16, 2023
∙ Paid

Novel oral anticoagulants including dabigatran, apixaban, and rivaroxaban have numerous advantages over warfarin, but with their shorter track record, the real-world relative efficacy of their reversal agents is poorly understood. In a meta-analysis of retrospective reviews comprising 1832 patients, the available reversal agents (4-factor prothrombin co…

Keep reading with a 7-day free trial

Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 PulmCCM LLC · Publisher Terms
Substack · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture